Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
It is very uncertain whether the intervention changes minimally invasive step‐up approach: video‐assisted vs. endoscopic (very low certainty).
It is very uncertain whether the intervention changes minimally invasive step‐up approach: video‐assisted vs. endoscopic (very low certainty).
It is very uncertain whether the intervention changes minimally invasive step‐up approach: video‐assisted vs. endoscopic (very low certainty).
It is very uncertain whether the intervention changes endoscopic drainage versus EUS‐guided drainage (very low certainty).
It is very uncertain whether the intervention changes endoscopic drainage versus EUS‐guided drainage (very low certainty).
It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).
It is very uncertain whether LMWH + standard therapy changes endoscopic remission compared with standard therapy (very low certainty).
It is very uncertain whether LMWH + standard therapy changes endoscopic improvement compared with standard therapy (very low certainty).
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
Budesonide 10 mg showed no clear difference in endoscopic improvement compared with prednisolone 40 mg (low certainty).
It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).
Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).
Budesonide MMX® 9 mg probably leads to higher endoscopic improvement compared with placebo (moderate certainty).